Scribd
Upload
668 views4 pages

HIV Topic Discussion Handout

The document discusses the history, epidemiology, viral life cycle, medication history, drug classes, treatment recommendations, and prevention of HIV/AIDS. It provides details on the initial cases, global prevalence and transmission routes, affected cell types, stages of infection, approved antiretroviral drug classes and regimens, opportunistic infection prophylaxis, pre-exposure prophylaxis, and references.

Uploaded by

Matthew Lei
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as DOCX, PDF, TXT or read online on Scribd
668 views4 pages

HIV Topic Discussion Handout

The document discusses the history, epidemiology, viral life cycle, medication history, drug classes, treatment recommendations, and prevention of HIV/AIDS. It provides details on the initial cases, global prevalence and transmission routes, affected cell types, stages of infection, approved antiretroviral drug classes and regimens, opportunistic infection prophylaxis, pre-exposure prophylaxis, and references.

Uploaded by

Matthew Lei
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as DOCX, PDF, TXT or read online on Scribd
You are on page 1/ 4

HIV Topic discussion

Matthew Lei, Pharm. D.


History
o June 5, 1981 CDC MMWR described P. jirovecii infections in five, previously healthy,
young gay men
o On September 24, CDC first used the term AIDS or acquired immune deficiency
syndrome
o Initial management of HIV composed of treatments for opportunistic infections and
subsequent palliative care
o Prevalence is increasing globally in spite of decreased new infections
o Advent of combination antiretroviral therapy (ART) in the mid-1990s reduced
transmission and prolonged survival
o Global AIDS related deaths reached a peak of 2.3 million in 2005, and decreased to
1.6 million in 2012
o Developments in the prevention of HIV include male medical circumcision,
antiretrovirals to prevent mother-to-child transmission, antiretroviral therapy in
people with HIV, and antiretrovirals for pre-exposure prophylaxis
Epidemiology
o HIV believed to be transmitted across species with simian immunodeficiency viruses
o HIV-1 was transmitted from apes; HIV-2 transmitted from sooty mangabey monkeys
o HIV-1 separated into four groups: M, N, O and P
o Group M, which consists of nine subtypes, is responsible for the global HIV
pandemic
o People living with HIV numbered 35.3 million in 2012
o People with HIV in high income countries on ART, 50% of death not due to AIDS
Non-AIDS defining cancers (23.5%)
Cardiovascular disease (15.7%)
Liver disease (14.1%)
o Main route of transmission for western and central Europe and the Americas is MSM
Viral life cycle
o In 1983, French researchers at Pasteur Institute in Paris isolated the AIDS virus
o HIV is a retrovirus consists of simple RNA, glycoproteins, reverse transcriptase,
integrase and protease enzymes
o Affected cells: activated CD4 T lymphocytes, resting CD4 T cells, monocytes,
macrophages, and dendritic cells
CD4 independent cells: astrocytes and renal epithelial cells
o In the acute phase, CD4+ cells will initially decline, but then increase and remain at
a setpoint
In the asymptomatic phase, From setpoint: (1) CD4 cells and gut immune
function will decrease linearly, (2) HIV RNA will increase linearly until the
patient develops AIDS, after which HIV RNA will increase exponentially
Medication history
o 1986, FDA approved first antiretroviral drug zidovudine (ZDV;AVT), NRTI
o Standard antiretroviral therapy between 1986 and 1995 was monotherapy
o Highly active antiretroviral therapy (HAART): 1997
o HAART decrease plasma viral RNA to undetectable within 3 months
Drug classes
o NRTI (chemical derivatives of purine- and pyrimidine-based nucleosides and
nucleotides)
Tenofovir (TDF), deoxyadenosine-monophosphate nucleotide analog
Emtricitabine (FTC), deoxycytidine analog
Lamivudine (3TC), deoxycytidine analog
Zidovudine (ZDV, AZT), thymidine analog

HIV Topic discussion


Matthew Lei, Pharm. D.
Abacavir (ABC), deoxyguanosine analog
*Stavudine (d4T), thymidine analog
*Didanosine (ddI), deoxyadenosine analog, an inosine derivative
o Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Efavirenz (EFV), Etravirine
(ETR), rilpivirine (RPV), nevirapine (NVP), delavirdine (DLV)
o Protease inhibitors (PIs): Atazanavir (ATV), darunavir (DRV), ritonavir (boosting dose:
/r), fosamprenavir (FPV), saquinavir (SQV), indinavir (IDV), nelfinavir (NFV),
tipranavir (TPV), ritonavir (fulldose: RTV)
o Fusion-inhibitor: Enfuvirtide (T20)
o CCR5-inhibitor: Maraviroc (MVC)
o Integrase inhibitor: Raltegravir (RAL)
Mechanism of action

Untreated HIV
o Post-clinical latency constitutional symptoms opportunistic infections death

Infectious agent

Pneumocystis jirovecii
Toxoplasma gondii
Histoplasma
capsulatum
Mycobacterium avium
Cytomegalovirus
Cryptococcus
neoformans

Indication per
CD4+ cell count
(cells/L)
<200
<100
<100 (endemic
areas)
< 50
<50
<50

Prophylaxis

TMP-SMX DS 1 tab daily


TMP-SMX DS 1 tab daily
Itraconazole 200 mg daily
Azithromycin 1200 mg weekly
None recommended
None recommended

Current recommendations for treatment


Recommended regimens for antiretroviral therapy (ART)-naive patients
Integrase Strand Transfer Inhibitor-Based Regimens:

HIV Topic discussion


Matthew Lei, Pharm. D.
Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mgonly for patients who are HLAB*5701 negative (AI)
Dolutegravir 50 mg plus tenofovir disoproxil fumarate (tenofovir) 300 mg/emtricitabine
200 mg (AI)
Elvitegravir 150 mg/cobicistat 150 mg/tenofovir 245 mg/emtricitabine 200 mgonly for
patients with pre-antiretroviral therapy CrCl >70 mL/min (AI)
Raltegravir 400 mg plus tenofovir 300 mg/emtricitabine 200 mg (AI)
Protease Inhibitor-Based Regimen:
Darunavir 600 mg/ritonavir 100 mg plus tenofovir 300 mg/emtricitabine 200 mg (AI)
Agents
Dolutegravi
r
Abacavir

Lamivudine

Tenofovir
Emtricitabi
ne
Raltegravir
Darunavir

Adverse events
Elevated LFTs/lipase, hyperglycemia, headache, insomnia
Contraindicated in HLA-B*5701 when positive, rash, N/V, headache,
sleep disorder, fatigue, fever, MI, SJS, TEN, lactic acidosis, hepatic
dysfunction
Diarrhea, nausea, headache, cough, nasal symptoms, fever,
malaise/fatigue, fat maldistribution, lactic acidosis, pancreatitis,
hepatomegaly
Renal impairment, associated with reduction in bone density
Lactic acidosis, hyperpigmentation, rash, abdominal pain/ diarrhea,
N/V, infectious disease, asthenia, depression, rhinitis, fatigue, lactic
acidosis
Nausea, insomnia, headache, fatigue, SJS, TEN, hypersensitivity,
rhabdomyolysis, suicidal, renal failure
Nausea, diarrhea, increased transaminases, headache, and rash

Pre-exposure prophylaxis
o Fetal and infant chemoprophylaxis
o Protection of healthcare workers from accidental exposure to HIV
o Cases of rape
o High-risk postcoital
HIV exposure prophylaxis
Significant risk of
Two NRTIs and a
exposure
boosted-PI
Lower risk of exposure

Two NRTIs

Emtricitabine and tenofovir approved for preventing sexual HIV acquisition

HIV Topic discussion

Matthew Lei, Pharm. D.

References
1. Lexicomp Online, Pediatric & Neonatal Lexi-Drugs, Hudson, Ohio: Lexi-Comp, Inc.;
August 13, 2015.
2. Maartens G, Celum C, Lewin S. HIV infection: epidemiology, pathogenesis, treatment, and
prevention. Lancet. 2014; 384(9939):258-71.
3. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of
antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and
Human Services. Available at
http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf.

You might also like

pFad - Phonifier reborn

Pfad - The Proxy pFad of © 2024 Garber Painting. All rights reserved.

Note: This service is not intended for secure transactions such as banking, social media, email, or purchasing. Use at your own risk. We assume no liability whatsoever for broken pages.


Alternative Proxies:

Alternative Proxy

pFad Proxy

pFad v3 Proxy

pFad v4 Proxy